US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Silexion Therapeutics Corp

9.28

-5.6600-37.88%

Post-market: 9.300.0200+0.22%19:58 EDT

Volume:360.35K

Turnover:3.35M

Market Cap:5.21M

PE:-0.02

High:11.10

Open:11.10

Low:7.82

Close:14.94

Loading ...

Overview Company News Filings

Crude Oil Down 2%; Amazon Shares Tumble After Q2 Results

Silexion Therapeutics Corp. Enters Inducement Offer with Warrant Holders for 152,106 Ordinary Shares

BUZZ-U.S. STOCKS ON THE MOVE-CNH Industrial, Newmont, Dominion Energy

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

Silexion Therapeutics Corp trading resumes

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

Silexion Therapeutics Corp. Announces Date for Extraordinary General Meeting

Silexion Therapeutics Corp. Announces 1-for-15 Reverse Share Split and Bylaw Amendments

Silexion Therapeutics Corp trading halted, news pending

Silexion Therapeutics Faces Nasdaq Listing Challenge Amid Bid Price Deficiency Warning

Silexion Therapeutics Corp. Announces Date for Extraordinary General Meeting

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Silexion Therapeutics Corp. Reconvened Annual General Meeting

Silexion Therapeutics Corp. Announces Positive Preclinical Results for SIL204 in Lung Cancer, Preparing for Phase 2/3 Clinical Trial in 2026

Silexion Therapeutics Corp. Announces 1-for-15 Reverse Stock Split Following Shareholder Approval

Silexion Therapeutics Corp. Appeals Nasdaq Delisting Notice; Securities Continue Trading Pending Hearing

Silexion Therapeutics Announces Promising Preclinical Results for SIL204, Targeting KRAS-Driven Cancers

Silexion Therapeutics announces preclinical results on SIL204

Silexion Therapeutics Corp. Faces Potential Nasdaq Delisting Due to Non-Compliance with Market Value Standards

Silexion Therapeutics completes preclinical studies on SIL204

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SLXN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLXN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":9.28,"timestamp":1754078400000,"preClose":14.94,"halted":0,"volume":360345,"hourTrading":{"tag":"盘后","latestPrice":9.3,"preClose":9.28,"latestTime":"19:58 EDT","volume":2829,"amount":26523.518,"timestamp":1754092722029},"delay":0,"floatShares":348780,"shares":560974,"eps":-395.362,"marketStatus":"Closed","change":-5.66,"latestTime":"08-01 16:00:00 EDT","open":11.1,"high":11.1,"low":7.82,"amount":3351862.526175,"amplitude":0.219545,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-395.362,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1754294400000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":14.94,"preHourTrading":{"tag":"盘前","latestPrice":11.13,"preClose":14.94,"latestTime":"09:29 EDT","volume":13314,"amount":157211.898396,"timestamp":1754054990638},"postHourTrading":{"tag":"盘后","latestPrice":9.3,"preClose":9.28,"latestTime":"19:58 EDT","volume":2829,"amount":26523.518,"timestamp":1754092722029},"volumeRatio":0.828438},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","floatShares":348780,"roa":"-193.54%","roe":"--","lyrEps":-395.36199,"volumeRatio":0.828438,"shares":560974,"dividePrice":0,"high":11.1,"amplitude":0.219545,"preClose":14.94,"low":7.82,"week52Low":7.82,"pbRate":"-1.31","week52High":1830.276,"institutionHeld":0,"latestPrice":9.28,"eps":-395.362,"divideRate":0,"volume":360345,"delay":0,"ttmEps":-395.362,"open":11.1,"prevYearClose":30.15,"prevWeekClose":12.954,"prevMonthClose":14.94,"prevQuarterClose":12.15,"fiveDayClose":12.954,"twentyDayClose":12.165,"sixtyDayClose":14.6565},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLXN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2556848547","title":"Crude Oil Down 2%; Amazon Shares Tumble After Q2 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2556848547","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556848547?lang=en_us&edition=fundamental","pubTime":"2025-08-02 01:44","pubTimestamp":1754070291,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/08/46804622/crude-oil-down-2-amazon-shares-tumble-after-q2-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","USJW.SI","LU0056508442.USD","SGXZ51526630.SGD","LU1778281490.HKD","LU0175139822.USD","LU0082616367.USD","IE00BFSS7M15.SGD","LU2077746001.SGD","NSP","LU2264538146.SGD","LU1935042215.USD","LU0029864427.USD","PHLT","QID","LU0823421416.USD","NQmain","MNQmain","LU1791710582.SGD","LU0256863811.USD","LU1868836591.USD","QLD","LU0077335932.USD","IE0009356076.USD","LU0256863902.USD","BK4130","TNON","AMZN","LU0072461881.USD","TQQQ","TSYW.SI","USAW.SI","SLXN","LU2168564149.EUR","ATEC","IE0004086264.USD","LU1814569148.SGD","LU2168563687.JPY","FLR","LU1868836757.USD","SGXZ23171101.USD","SQQQ","LU1235294995.USD","LU2087625088.SGD","LU2054465674.USD","NVIW.SI","PSQ",".IXIC","LU2265009873.SGD"],"gpt_icon":1},{"id":"2556810532","title":"Silexion Therapeutics Corp. Enters Inducement Offer with Warrant Holders for 152,106 Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2556810532","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556810532?lang=en_us&edition=fundamental","pubTime":"2025-08-02 00:29","pubTimestamp":1754065795,"startTime":"0","endTime":"0","summary":"On July 31, 2025, Silexion Therapeutics Corp. entered into an inducement offer letter agreement with certain holders of 152,106 existing warrants. These warrants, originally issued in January 2025, were exercised for cash at a reduced price of $11.57 per share. In return, Silexion agreed to issue new warrants for 304,212 ordinary shares at an exercise price of $11.32 per share. The company anticipates gross proceeds of approximately $1.8 million from the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nNDL5fcx34:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2556817480","title":"BUZZ-U.S. STOCKS ON THE MOVE-CNH Industrial, Newmont, Dominion Energy","url":"https://stock-news.laohu8.com/highlight/detail?id=2556817480","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556817480?lang=en_us&edition=fundamental","pubTime":"2025-08-01 23:44","pubTimestamp":1754063098,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-CNH Industrial, Newmont, Dominion EnergyEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nL6N3TT0MZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNH","LU1069347547.HKD","SLXN","PHM","NEM","MX","LU1093756168.USD","LU2462157665.USD","LU2552382132.HKD","OBIO","MRNA","CVX","DHI","GSK.UK","LU0545562505.USD","LU0566484027.USD","SGBX","XOM","IR","AES","MPWR","ROKU","LU0321505868.SGD","FSLR","SG9999013999.USD","03165","EMN","KMB","TNON","FLR","WK","D","GWW","CPS","LEN","AZN.UK","601899","LOBO","PHLT","LU1232071149.USD","DOUG","BK4534","LYB"],"gpt_icon":1},{"id":"2556570758","title":"Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2556570758","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556570758?lang=en_us&edition=fundamental","pubTime":"2025-08-01 08:00","pubTimestamp":1754006400,"startTime":"0","endTime":"0","summary":"Cayman Islands, July  31, 2025  (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech company developing RNA interference ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/01/3125550/0/en/Silexion-Therapeutics-Announces-Exercise-of-Warrants-for-1-8-Million-Gross-Proceeds.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139","BK4007","BK4539","LENZ"],"gpt_icon":0},{"id":"2555839054","title":"Silexion Therapeutics Corp trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2555839054","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555839054?lang=en_us&edition=fundamental","pubTime":"2025-07-31 22:15","pubTimestamp":1753971329,"startTime":"0","endTime":"0","summary":"10:10 EDT Silexion Therapeutics (SLXN) Corp trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking f...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-corp-trading-resumes-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-corp-trading-resumes-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2555834674","title":"Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation","url":"https://stock-news.laohu8.com/highlight/detail?id=2555834674","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555834674?lang=en_us&edition=fundamental","pubTime":"2025-07-31 21:55","pubTimestamp":1753970100,"startTime":"0","endTime":"0","summary":"New Results Reveal Unprecedented Inhibition Rates and First Evidence of SIL204's Efficacy Against Previously Untested KRAS Q61H Mutation in Human Cancer Cells, Significantly Expanding its Pan-KRAS Pot","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/31/3125114/0/en/Silexion-Therapeutics-Announces-New-Preclinical-Data-Showing-Up-to-97-Inhibition-of-Cancer-Cell-Growth-Including-New-Evidence-Against-New-Previously-Untested-KRAS-Mutation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN","BK4007","LENZ","BK4539"],"gpt_icon":0},{"id":"2555351408","title":"Silexion Therapeutics Corp. Announces Date for Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2555351408","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555351408?lang=en_us&edition=fundamental","pubTime":"2025-07-31 21:14","pubTimestamp":1753967681,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp is set to hold an extraordinary general meeting on August 12, 2025, at Meitar Law Offices in Ramat Gan, Israel. During the meeting, shareholders will consider and vote on the proposal for an authorized share capital increase.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 31, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nNDLbmdqb1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2555051497","title":"Silexion Therapeutics Corp. Announces 1-for-15 Reverse Share Split and Bylaw Amendments","url":"https://stock-news.laohu8.com/highlight/detail?id=2555051497","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555051497?lang=en_us&edition=fundamental","pubTime":"2025-07-29 21:11","pubTimestamp":1753794684,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp. has announced amendments to its bylaws following shareholder approval of a 1-for-15 reverse share split. Effective July 28, 2025, the company's ordinary shares will trade on a split-adjusted basis on Nasdaq. The reverse split, approved at the 2025 Annual General Meeting, decreases issued and outstanding shares while maintaining the authorized share capital at $20,000, adjusting the par value of shares from $0.0009 to $0.0135. The trading symbol \"SLXN\" remains unchanged.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securitie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nNDLN2vL9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2555707847","title":"Silexion Therapeutics Corp trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2555707847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555707847?lang=en_us&edition=fundamental","pubTime":"2025-07-29 07:50","pubTimestamp":1753746616,"startTime":"0","endTime":"0","summary":"19:50 EDT Silexion Therapeutics (SLXN) Corp trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-movi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-corp-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-corp-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2553250409","title":"Silexion Therapeutics Faces Nasdaq Listing Challenge Amid Bid Price Deficiency Warning","url":"https://stock-news.laohu8.com/highlight/detail?id=2553250409","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553250409?lang=en_us&edition=fundamental","pubTime":"2025-07-22 04:06","pubTimestamp":1753128376,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp. has received a notice from the Nasdaq Stock Market LLC regarding a regulatory issue related to its stock listing. The Listing Qualifications Department informed Silexion that the closing bid price of its ordinary shares has been below the minimum $1.00 per share requirement for 30 consecutive business days, as per Nasdaq Listing Rule 5550. This bid price deficiency could impact Silexion's continued listing on the Nasdaq Capital Market. While the letter does not immediately affect the trading of Silexion's ordinary shares or warrants, it will be considered by the Nasdaq hearings panel in deciding whether the company can remain listed. Silexion has until September 19, 2025, to meet compliance terms and achieve the required standards for listing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250721:nNDL371tJy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2553031454","title":"Silexion Therapeutics Corp. Announces Date for Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2553031454","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553031454?lang=en_us&edition=fundamental","pubTime":"2025-07-22 00:06","pubTimestamp":1753114016,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp is set to hold an extraordinary general meeting in August 2025 at Meitar Law Offices, Ramat Gan, Israel. During the meeting, shareholders will consider and vote on the proposal concerning the authorized share capital increase.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 21, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250721:nNDLchlHkh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2551123582","title":"Silexion Therapeutics Announces 1-for-15 Reverse Share Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2551123582","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551123582?lang=en_us&edition=fundamental","pubTime":"2025-07-16 20:44","pubTimestamp":1752669840,"startTime":"0","endTime":"0","summary":"Trading on split-adjusted basis will begin at market open on July 29, 2025. This adjustment is expected to help Silexion comply with NASDAQ requirements, enhance its market position, and support its s","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/16/3116419/0/en/Silexion-Therapeutics-Announces-1-for-15-Reverse-Share-Split.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4007","BK4539","LENZ","NVIW.SI","BK4139","QLD","SQQQ","MNQmain",".IXIC","USJW.SI","TQQQ","TSYW.SI","USAW.SI","NQmain","QID","PSQ"],"gpt_icon":1},{"id":"2551943135","title":"Silexion Therapeutics Corp. Reconvened Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2551943135","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551943135?lang=en_us&edition=fundamental","pubTime":"2025-07-15 04:06","pubTimestamp":1752523578,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp. reconvened its 2025 annual general meeting on July 14, 2025. The shareholders approved the election of Ilan Hadar, Dror J. Abramov, Ruth Alon, Ilan Levin, Avner Lushi, Shlomo Noy, and Amnon Peled as directors on the board. The appointment of Kesselman & Kesselman as independent public accountants for the year ending December 31, 2025, was ratified. Additionally, a proposal to allow the board to effect a reverse share split of the company's ordinary shares at a ratio of 1-for-15 was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system ope","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDL6Y4r0f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2550658349","title":"Silexion Therapeutics Corp. Announces Positive Preclinical Results for SIL204 in Lung Cancer, Preparing for Phase 2/3 Clinical Trial in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2550658349","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550658349?lang=en_us&edition=fundamental","pubTime":"2025-07-09 21:16","pubTimestamp":1752066984,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp. Announces Positive Preclinical Results for SIL204 in Lung Cancer, Preparing for Phase 2/3 Clinical Trial in 2026. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 09, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nNDL15C36n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2549528873","title":"Silexion Therapeutics Corp. Announces 1-for-15 Reverse Stock Split Following Shareholder Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2549528873","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549528873?lang=en_us&edition=fundamental","pubTime":"2025-07-08 21:36","pubTimestamp":1751981767,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp. has announced plans to implement a 1-for-15 reverse share split following its 2025 annual general meeting, scheduled for completion on July 14, 2025. This move aims to address a bid price deficiency and is anticipated to take effect around July 25, 2025, pending shareholder approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDLcgYRqg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2540570417","title":"Silexion Therapeutics Corp. Appeals Nasdaq Delisting Notice; Securities Continue Trading Pending Hearing","url":"https://stock-news.laohu8.com/highlight/detail?id=2540570417","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540570417?lang=en_us&edition=fundamental","pubTime":"2025-06-04 04:06","pubTimestamp":1748981190,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp., a Cayman Islands-based company, is currently facing a delisting process from the Nasdaq Global Market due to non-compliance with required market value standards. The company received a delisting notice after failing to rectify these deficiencies by the designated deadline of May 19, 2025. In response, Silexion has requested a hearing to appeal the delisting notice, which has temporarily stayed the process and allowed its securities to continue trading under the symbols \"SLXN\" and \"SLXNW.\" As part of its strategy, Silexion plans to apply for a transfer of its listing to the Nasdaq Capital Market. The hearing date has not been specified, but the appeal process allows continued trading until the hearing occurs.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL8DbGSy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2539660172","title":"Silexion Therapeutics Announces Promising Preclinical Results for SIL204, Targeting KRAS-Driven Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2539660172","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539660172?lang=en_us&edition=fundamental","pubTime":"2025-05-29 22:15","pubTimestamp":1748528107,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp., a clinical-stage biotechnology company specializing in RNA interference  therapies for KRAS-driven cancers, has announced noteworthy preclinical results for its therapeutic candidate, SIL204. The data demonstrates SIL204's efficacy in inhibiting tumor proliferation across pancreatic, colorectal, and lung cancer cell lines, each harboring the KRAS G12D mutation. The study revealed a significant inhibition rate of approximately 90% in GP2D human colorectal cancer cells. SIL204 utilizes a lipid-conjugated delivery system to enhance the uptake and concentration of small interfering RNA  within cells, showing potential for low-dose effectiveness. These findings suggest expanded therapeutic applications for SIL204, with Silexion planning further preclinical studies focused on lung cancer cell lines. The company's RNAi approach addresses a substantial unmet medical need in treating KRAS-driven cancers, which represent a large market with limited current treatment ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL6v8DZb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2539632562","title":"Silexion Therapeutics announces preclinical results on SIL204","url":"https://stock-news.laohu8.com/highlight/detail?id=2539632562","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539632562?lang=en_us&edition=fundamental","pubTime":"2025-05-29 21:10","pubTimestamp":1748524221,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics (SLXN) announced compelling preclinical data demonstrating the efficacy of its next-generation RNAi therapeutic candidate, SI...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-announces-preclinical-results-on-sil204-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-announces-preclinical-results-on-sil204-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","SLXN","BK4539","BK4007"],"gpt_icon":0},{"id":"2537157381","title":"Silexion Therapeutics Corp. Faces Potential Nasdaq Delisting Due to Non-Compliance with Market Value Standards","url":"https://stock-news.laohu8.com/highlight/detail?id=2537157381","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537157381?lang=en_us&edition=fundamental","pubTime":"2025-05-24 05:00","pubTimestamp":1748034050,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp, a Cayman Islands-based company, announced on May 22, 2025, that it received a delisting notice from the Nasdaq Listing Qualifications Department. The notice pertains to the company's failure to comply with Nasdaq Listing Rules 5450 and 5450, which require maintaining a minimum Market Value of Listed Securities of $50 million and a Market Value of Publicly Held Shares of $15 million. Despite a 180-day compliance period ending May 19, 2025, Silexion was unable to rectify these deficiencies. The company plans to appeal the decision before the Nasdaq Hearings Panel by May 29, 2025. If the appeal is unsuccessful, trading of its shares and warrants will be suspended on June 2, 2025, and a Form 25-NSE will be filed with the SEC to remove its securities from Nasdaq listing. Additionally, Silexion intends to apply for a transfer to the Nasdaq Capital Market, contingent upon meeting the required Equity Standard.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nNDL3Vt7Yf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2537353869","title":"Silexion Therapeutics completes preclinical studies on SIL204","url":"https://stock-news.laohu8.com/highlight/detail?id=2537353869","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537353869?lang=en_us&edition=fundamental","pubTime":"2025-05-21 20:50","pubTimestamp":1747831822,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics (SLXN) announced the completion of a comprehensive preclinical study assessing SIL204’s therapeutic potential across multiple...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-completes-preclinical-studies-on-sil204?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-completes-preclinical-studies-on-sil204?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4539","SLXN","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":34,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLXN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-07-29","symbol":"SLXN","defaultRemindTime":1753795800000,"type":"split","dateTimestamp":1753761600000,"forFactor":15,"toFactor":1,"ratio":15},{"market":"US","date":"2024-11-29","symbol":"SLXN","defaultRemindTime":1732890600000,"type":"split","dateTimestamp":1732856400000,"forFactor":9,"toFactor":1,"ratio":9},{"market":"US","date":"2024-08-13","symbol":"SLXN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLXN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1730520000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLXN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLXN","date":"2025-07-31","current":-0.386196,"percent":0.984615,"low":-0.532214,"twenty":-0.496494,"median":-0.461645,"eighty":-0.415025,"high":-0.355662,"avg":-0.456507,"sd":0.041369,"marketCap":6350225},"quantilePoints":[{"date":"2025-05-02","current":-0.511745,"twenty":-0.505522,"median":-0.478123,"eighty":-0.462658,"marketCap":8414615},{"date":"2025-05-09","current":-0.508623,"twenty":-0.511745,"median":-0.504017,"eighty":-0.475134,"marketCap":8363285},{"date":"2025-05-16","current":-0.49368,"twenty":-0.511295,"median":-0.503966,"eighty":-0.488849,"marketCap":8117579},{"date":"2025-05-23","current":-0.504427,"twenty":-0.509135,"median":-0.49826,"eighty":-0.470682,"marketCap":8294286},{"date":"2025-05-30","current":-0.491275,"twenty":-0.511407,"median":-0.49826,"eighty":-0.475032,"marketCap":8078030},{"date":"2025-06-06","current":-0.471573,"twenty":-0.511407,"median":-0.49368,"eighty":-0.475196,"marketCap":7754067},{"date":"2025-06-13","current":-0.453201,"twenty":-0.509647,"median":-0.491403,"eighty":-0.471409,"marketCap":7451983},{"date":"2025-06-20","current":-0.41963,"twenty":-0.506945,"median":-0.488844,"eighty":-0.464552,"marketCap":6899984},{"date":"2025-06-27","current":-0.415025,"twenty":-0.504283,"median":-0.484008,"eighty":-0.449824,"marketCap":6824252},{"date":"2025-07-03","current":-0.415025,"twenty":-0.504048,"median":-0.478123,"eighty":-0.41963,"marketCap":6824252},{"date":"2025-07-11","current":-0.42265,"twenty":-0.503966,"median":-0.474592,"eighty":-0.417174,"marketCap":6949630},{"date":"2025-07-18","current":-0.440049,"twenty":-0.503178,"median":-0.468758,"eighty":-0.415025,"marketCap":7235727},{"date":"2025-07-25","current":-0.430889,"twenty":-0.49932,"median":-0.464408,"eighty":-0.415332,"marketCap":7085105},{"date":"2025-07-31","current":-0.386196,"twenty":-0.496494,"median":-0.461645,"eighty":-0.415025,"marketCap":6350225}],"updateTime":1754102209873}}}